Table 2.
Performance Characteristics for NR4A3 in Acinic Cell Carcinoma and Other Primary Salivary Gland Neoplasms in Cytologic and Surgical Specimens (n = 135)
| Tumor Type | Specimen Type (No.) | NR4A3 Positive, No. (%) |
|---|---|---|
| Acinic cell carcinoma (n = 29) | SR (9) | 9/9 (100) |
| CB (20) | 18/20 (90) | |
| Acinic cell carcinoma with high-grade transformation (n = 3) | SR (3) | 3/3 (100) |
| Warthin tumor (n = 43) | SR (31) | 0/31 (0) |
| CB (19) | 0/19 (10) | |
| Mucoepidermoid carcinoma (n = 16) | SR (15) | 1/15 (6.7) |
| CB (6) | 0/6 (0) | |
| Secretory carcinoma (n = 10) | SR (7) | 0/7 (0) |
| CB (3) | 0/3 (0) | |
| Pleomorphic adenoma (n = 6) | SR (6) | 0/6 (0) |
| CB (2) | 0/2 (0) | |
| Carcinoma ex-pleomorphic adenoma (n = 2) | SR (2) | 0/2 (0) |
| Cellular pleomorphic adenoma (n = 1) | SR (1) | 0/1 (0) |
| CB (1) | 0/1 (0) | |
| Oncocytic carcinoma (n = 1) | SR (1) | 0/1 (0) |
| Oncocytoma (n = 19) | SR (18) | 0/18 (0) |
| CB (5) | 0/5 (0) | |
| Nodular oncocytosis (n = 5) | SR (5) | 0/5 (0) |
CB, cell block; NR4A3, nuclear receptor subfamily 4 group A member 3; SR, surgical resection.